(SAGE) - Earnings & Price History

SAGE: - 62.9, $2.36B, -2.09 (-3.22%)

Sector: Healthcare - Industry: Biotechnology

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The companys lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). It is also conducting an additional Phase II exploratory trial of SAGE-547 in the treatment of severe post-partum depression (PPD). In addition, its pipeline includes next-generation product candidates, such as SAGE-217, a novel neuroactive steroid, which is in Phase I clinical trial for the treatment of orphan epilepsies and essential tremor, as well as for PPD; and SAGE-689, an acute adjunctive IV therapy for the treatment of indications where a high degree of anti-seizure activity and sedati

Past SAGE reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-02-23BMO-1.1962.3361.9361.5360.5765.22-0.65%1.30%0.65%710.60K
2016-11-03BMO-1.138.7141.2143.7538.3446.16%-11.52%-6.07%902.61K
2016-08-09BMO-1.0236.8642.4636.4635.6440.49-14.13%▲1.10%-13.19%2.40M
2016-05-05BMO-0.9834.7935.1635.1734.0735.620.03%-1.08%-1.05%371.73K
2016-02-24BMO-0.9430.7532.1131.3728.9731.39-2.30%-1.98%-4.24%665.27K
2015-08-12-0.6859.7562.4762.8958.1266.970.67%▲-4.99%-4.35%485.78K
2015-05-14-0.4958.4458.2961.0356.4364.994.70%-4.24%0.26%394.86K
2014-11-13Sage Therapeutc-0.47-0.535.4435.0635.1934.8336.060.37%0.71%1.08%71.30K

Login | Register
Sunday Sep 24, 2017   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY249.440.050.02%51,191,873

Upgrades/Downgrades